The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Open accessAbstract
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P=0.98). There were no significant between-group differences in rates of acute pancreatitis (P=0.07) or pancreatic cancer (P=0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp & Dohme; TECOS ClinicalTrials.gov number, NCT00790205.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“have shown that DPP4i exhibit cardiovascular neutrality in T2DM patients.”
From The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis (2025) · cites this paper as [136]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across the trials of this drug class, there appears to be no interaction by age-group (110-112).”
From 13. Older Adults: Standards of Care in Diabetes—2024 (2024) · cites this paper as [111]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, three other cardiovascular outcomes trials-Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (293), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (294), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (295)-did not find a significant increase in risk of heart failure hospitalization with D”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [294]
The cited source says what the claim attributes to it.
In the citing paper
“However, three other cardiovascular outcomes trials—Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) (312), Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (313), and the Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) (314)—did not find a significant increase in risk of heart failure hospitalization with D”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [313]
The cited source says what the claim attributes to it.
In the citing paper
“The comparator, sitagliptin, served as a placebo proxy regarding the outcome of interest as it showed no effect on heart failure events in a major randomized clinical trial and previously successfully served as a placebo proxy in claims data analyses.15,18,19”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [19]
In the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [31]
In the citing paper
“Excepting glimepiride, which was assessed for CV safety and efficacy head-to-head against linagliptin in the CAROLINA trial, and gliclazidemodified release, which was compared with usual care (that could have included treatment with a sulphonylurea other than gliclazide) in the ADVANCE trial, dedicated CV safety assessments have not been conducted for the other sulphonylureas.132,173,174,184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [174]
In the citing paper
“Sitagliptin and linagliptin had a neutral effect.174,[178][179][180]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [174]
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [215]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [18]
In the citing paper
“Likewise, sitagliptin in the TECOS trial had no signal of excess rates of HF. 18,185”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [18]
In the citing paper
“In mice, GLP-1 causes vasodilation through both GLP-1 receptor-dependent and -independent mechanisms.211”
From The Vasculature in Prediabetes (2018) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Self-citationEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
The role of gut hormones in glucose homeostasis
Drucker, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30076 · Cited by 628
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,006
Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort
Mirani, M., Favacchio, G., Serone, E., Lucisano, G., Rossi, M. C., & Berra, C. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.003 · Cited by 31
Cardiovascular Protection with Anti-hyperglycemic Agents
DEEDWANIA, P. C., & Acharya, T. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00325-9 · Cited by 31
Ramos, M., FOOS, V., Ustyugova, A., Hau, N., Gandhi, P., & Lamotte, M. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00701-3 · Cited by 31
Furuhashi, M., Sakuma, I., Morimoto, T., Higashiura, Y., Sakai, A., Matsumoto, M., Sakuma, M., Shimabukuro, M., Nomiyama, T., Arasaki, O., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01061-0 · Cited by 32
Hadidi, S. E., Rosano, G. M. C., Tamargo, J. L., Agewall, S., Drexel, H., Kaski, J. C., Niessner, A., Lewis, B. S., Coats, A. J. S., & Savarese, G. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa108 · Cited by 32
Wood, N., Straw, S., Scalabrin, M., Roberts, L. D., Witte, K. K., & Bowen, T. S. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13121 · Cited by 31
Reifsnider, O. S., Kansal, A., Pimple, P. M., Ribero, V. A., Brand, S. B., & Shetty, S. S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14268 · Cited by 31
Htoo, P. T., Tesfaye, H., Schneeweiß, S., Wexler, D. J., Everett, B. M., Glynn, R. J., Kim, S. C., Najafzadeh, M., Koeneman, L., FARSANI, S. F. F., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.37606 · Cited by 31
Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes
Lau, D. C. W., & Teoh, H. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.09.090 · Cited by 33
When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
Avogaro, A., Delgado, E., & Lingvay, I. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2981 · Cited by 34
Understanding EMPA-REG OUTCOME
Ceriello, A., Genovese, S., Mannucci, E., & Gronda, E. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00426-x · Cited by 31
Lee, W., Kipp, Z. A., Pauss, S. N., Martinez, G. J., Bates, E. A., Badmus, O. O., Stec, D. E., & Hinds, T. D. (2025) · Clinical Science · doi:10.1042/cs20242825 · Cited by 30
Widlansky, M. E., Puppala, V. K., Suboc, T. M. B., Malik, M. A., Branum, A., Signorelli, K., Wang, J., Ying, R., Tanner, M. J., & Tyagi, S. (2017) · Vascular Medicine · doi:10.1177/1358863x16681486 · Cited by 30
NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions
Welters, A., Kluppel, C. A., Mrugala, J., Wörmeyer, L., Meißner, T., Mayatepek, E., Heiß, C., Eberhard, D., & Lammert, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13017 · Cited by 34
Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes
Abrahami, D., Yin, H., Yu, O. H. Y., Pollak, M., & Azoulay, L. (2017) · Epidemiology · doi:10.1097/ede.0000000000000793 · Cited by 30
Li, Y., Tsai, S., Chen, D., Chen, S., Sun, J., Chang, H., Liou, M., & Chen, T. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0655-y · Cited by 30
Davis, T. M. E., Mulder, H. S., Lokhnygina, Y. V., Aschner, P. J., Chuang, L., Grado, C. A. R., Standl, E., Peterson, E. D., Holman, R. R., & for the TECOS Study Group (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13242 · Cited by 30
Self-citationMetabolic Karma—The Atherogenic Legacy of Diabetes: The 2017 Edwin Bierman Award Lecture
Cooper, M. E., El‐Osta, A., Allen, T. J., Watson, A. M. D., Thomas, M. C., & Jandeleit-Dahm, K. A. M. (2018) · Diabetes · doi:10.2337/dbi18-0010 · Cited by 30
A practical Bayesian adaptive design incorporating data from historical controls
Psioda, M. A., Soukup, M., & Ibrahim, J. G. (2018) · Statistics in Medicine · doi:10.1002/sim.7897 · Cited by 30
Singh, A. K., Gangopadhyay, K. K., & Singh, R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1736041 · Cited by 31
Menon, V., Kumar, A., Patel, D. R., John, J. S., Riesmeyer, J., Weerakkody, G. J., Ruotolo, G., Wolski, K., McErlean, E. S., Cremer, P. C., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000943 · Cited by 31
Chiang, C., Ueng, K.-C., Chao, T., Lin, T., Wu, Y.-J., Wang, K.-L., Sung, S., Yeh, H., Li, Y., Liu, P., et al. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000359 · Cited by 30
Zhou, J., Wu, B., Wang, W., Lei, F., Cheng, X., Qin, J., Cai, J., Zhang, X., Zhou, F., Liu, Y.-M., et al. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i22.5576 · Cited by 30
Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues
Longo, M., Scappaticcio, L., Cirillo, P., Maio, A., Carotenuto, R. M., Maiorino, M. I., Bellastella, G., & Esposito, K. (2022) · Biomolecules · doi:10.3390/biom12020272 · Cited by 30
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 32
Wang, H., Cordiner, R. L. M., Huang, Y., Donnelly, L. A., Hapca, S. M., Collier, A., McKnight, J. A., Kennon, B., Gibb, F. W., McKeigue, P., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1238 · Cited by 30
Fu, E. L., Patorno, E., Everett, B. M., Vaduganathan, M., Solomon, S. D., Levin, R., Schneeweiß, S., & Desai, R. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad273 · Cited by 30
Wang, H., Liu, Y., Tian, Q., Yang, J., Lu, R., Zhan, S., Haukka, J. K., & Hong, T. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13177 · Cited by 30
Cardiovascular effects of sitagliptin – An anti‐diabetes medicine
Zhou, Y., Guo, Z., Yan, W., & Wang, W. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12953 · Cited by 30
Packer, M. (2018) · Circulation · doi:10.1161/circulationaha.117.032190 · Cited by 30
Evidence-Based Management of Diabetes in Older Adults
Mooradian, A. D. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0598-3 · Cited by 31
Li, S., Qin, C., Cui, S., Xu, H., Wu, F., Wang, J., Su, M., Fang, X., Li, D., Jiao, Q., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01491 · Cited by 30
Singh, A. K., & Singh, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1588110 · Cited by 31
Tanaka, A., & Node, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0731-y · Cited by 31
Małyszczak, A., Przeździecka-Dołyk, J., Szydełko-Paśko, U., & Misiuk‐Hojło, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061797 · Cited by 29
Triplitt, C. L., Solis‐Herrera, C., Cersósimo, E., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1114098 · Cited by 29
Sato, A., Yoshihisa, A., Kanno, Y., Takiguchi, M., Miura, S., Shimizu, T., Nakamura, Y., Yamauchi, H., Owada, T., Sato, T., et al. (2015) · ESC Heart Failure · doi:10.1002/ehf2.12079 · Cited by 29
for the PROLOGUE Study Investigators, Maruhashi, T., Higashi, Y., Kihara, Y., Yamada, H., Sata, M., Ueda, S., Odawara, M., Terauchi, Y., Dai, K., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0438-x · Cited by 29
Cardiovascular outcome trials of the newer anti-diabetic medications
Acharya, T., & DEEDWANIA, P. C. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.08.003 · Cited by 29
Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes
Razavi-Nematollahi, L., & Ismail‐Beigi, F. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1266-7 · Cited by 31
Pleiotropic effects of anti-diabetic drugs: A comprehensive review
Nath, M., Bhattacharjee, K., & Choudhury, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173349 · Cited by 33
Yang, W., Cai, X., Zhang, S., Han, X., & Ji, L. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3391 · Cited by 29
Contemporary Management of Heart Failure in Patients With Diabetes
Shaw, J. A., & Cooper, M. E. (2020) · Diabetes Care · doi:10.2337/dc20-2173 · Cited by 29
Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
Kang, S. M., & Park, J. H. (2021) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514211051698 · Cited by 31
Ceriello, A., & Inagaki, N. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12528 · Cited by 31
Xu, S., Zhang, X., Tang, L., Zhang, F., & Tong, N. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1255537 · Cited by 30
Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease
Khan, H., Anker, S. D., Januzzi, J. L., McGuire, D. K., Sattar, N. A., Woerle, H. J., & Butler, J. (2018) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2018.10.015 · Cited by 29
Self-citationBertoluci, M. C., Salles, J. E. N., Silva‐Nunes, J., Pedrosa, H. C., Moreira, R. O., Duarte, R., Carvalho, D. M., Trujilho, F. R., Raposo, J. F. C. D. S., Parente, E. B., et al. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00551-1 · Cited by 31
Taylor, O. M., & Lam, C. (2020) · Current Therapeutic Research · doi:10.1016/j.curtheres.2020.100596 · Cited by 33
GLP-1 RAs and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Chen, T., Hu, E.-H., Chen, D., Lin, Y., Chou, T., Lin, M., Yang, N., Wang, C., Hung, M., & Tsai, M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.30952 · Cited by 28
Ismail‐Beigi, F., Moghissi, E. S., Kosiborod, M., & Inzucchi, S. E. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4061-7 · Cited by 28
Toh, S., Reichman, M. E., Graham, D. J., Hampp, C., Zhang, R., Butler, M. G., Iyer, A., Rucker, M., Pimentel, M., Hamilton, J., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0476 · Cited by 28
Trends in Diabetes Treatment and Monitoring among Medicare Beneficiaries
Landon, B. E., Zaslavsky, A. M., Souza, J., & Ayanian, J. Z. (2018) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4310-4 · Cited by 28
Liraglutide relieves cardiac dilated function than DPP ‐4 inhibitors
Hiramatsu, T., Asano, Y., Mabuchi, M., Imai, K., Iguchi, D., & Furuta, S. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13007 · Cited by 28
Cosenso‐Martin, L. N., Giollo-Júnior, L. T., Fernandes, L. A. B., Cesarino, C. B., Nakazone, M. A., Machado, M. D. N., Yugar‐Toledo, J. C., & Vilela-Martin, J. F. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1204-1 · Cited by 28
Chen, Y.-C., Chen, T., Sun, C.-C., Chen, J., Chang, S.-S., Yeung, L., & Tsai, Y. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01533-5 · Cited by 28
Saisho, Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1776262 · Cited by 28
Ding, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 28
Reifsnider, O. S., Kansal, A. R., Gandhi, P., Cragin, L. S., Brand, S. B., Pfarr, E., Fahrbach, K. R., & Ustyugova, A. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001313 · Cited by 28
Karhunen, V., Daghlas, I., Zuber, V., Vujkovic, M., Olsen, A. K., Knudsen, L. B., Haynes, W. G., Howson, J. M. M., & Gill, D. (2021) · Diabetologia · doi:10.1007/s00125-021-05564-7 · Cited by 28
Lorenzo-Almorós, A., Cepeda-Rodrigo, J. M., & Lorenzo, Ó. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2019.10.013 · Cited by 31
Foley, J. E., Evans, M., & Schweizer, A. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s112148 · Cited by 28
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
Quartuccio, M., Buta, B. J., & Kalyani, R. R. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0215-z · Cited by 29
Gazzaruso, C., Fodaro, M., & Coppola, A. (2016) · Endocrine · doi:10.1007/s12020-016-0947-0 · Cited by 28
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 27
Self-citationLiao, K., Lin, C., Lai, S., & Chen, W. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.09.015 · Cited by 27
Diabetes for Cardiologists: Practical Issues in Diagnosis and Management
Mancini, G. B. J., CHENG, A. Y. Y., Connelly, K. A., FITCHETT, D. H., Goldenberg, R., Goodman, S. G., Leiter, L. A., Lonn, E., Paty, B. W., Poirier, P., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.512 · Cited by 27
Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus
Yandrapalli, S., & Aronow, W. S. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.06.70 · Cited by 27
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
Wang, X., Yang, L., Cheng, Y., Zheng, P., Hu, J., Huang, G., & Zhou, Z. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12873 · Cited by 27
Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs
Alfayez, O. M., Yami, M. S. A., Alshibani, M., Fallatah, S., Alkhushaym, N., Alsheikh, R., & Alkhatib, N. S. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.01.003 · Cited by 27
5 Conservative treatment for PAD – Risk factor management
Frank, U., Nikol, S., & Belch, J. J. F. (2019) · VASA · doi:10.1024/0301-1526/a000835 · Cited by 27
González, C. L., Atienza, E., Reyes-Umpierrez, D., Vellanki, P., Davis, G. M., Pasquel, F. J., Cardona, S., Fayfman, M., Peng, L., & Umpierrez, G. E. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0481 · Cited by 27
Mechanisms and pharmacotherapy of hypertension associated with type 2 diabetes
Kamalumpundi, V., Shams, E., Tucker, C., Cheng, L., Peterson, J., Thangavel, S., Ofori, O., & Correia, M. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115304 · Cited by 27
Green, J. B., Everett, B. M., Ghosh, A., Younes, N., Krause-Steinrauf, H. J., Barzilay, J. I., Desouza, C. V., Inzucchi, S. E., Pokharel, Y., Schade, D. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066604 · Cited by 28
Self-citationLeung, M., Leung, D. Y., & Wong, V. W. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116629352 · Cited by 27
Kalra, S. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0197-4 · Cited by 28
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1258401 · Cited by 27
Yoon, S. A., Han, B. G., Kim, S. G., Han, S. Y., Jo, Y. I., Jeong, K. H., Oh, K.-H., Park, H. C., Park, S. H., Kang, S., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12863 · Cited by 27
Atkin, S. L., Katsiki, N., Banach, M., Mikhailidis, D. P., Pirro, M., & Sahebkar, A. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.05.016 · Cited by 27
Sharma, M., Beckley‐Hoelscher, N., Nazareth, I., & Petersen, I. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017260 · Cited by 27
Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
Koyani, C. N., Trummer, C., Shrestha, N., Scheruebel, S., Bourgeois, B. M. R., Plastira, I., Kickmaier, S., Sourij, H., Rainer, P. P., Madl, T., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01622 · Cited by 27
Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus
Shin, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1171-0 · Cited by 27
Piechocki, M., Przewłocki, T., Pieniążek, P., Trystuła, M., Podolec, J., & Kabłak-Ziembicka, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051508 · Cited by 29
Fichadiya, A., Quinn, A. E., Au, F., Campbell, D. B., Lau, D., Ronksley, P. E., Beall, R. F., Campbell, D. J. T., Wilton, S. B., & Chew, D. S. (2024) · EP Europace · doi:10.1093/europace/euae054 · Cited by 26
Hirshberg, B., & Katz, A. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0663-9 · Cited by 26
Cardiovascular Effects of Incretin-Based Therapies
White, W. B., & Baker, W. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-050214-013431 · Cited by 26
Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus
Trang, A., & Aguilar, D. A. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0371-7 · Cited by 26
Kim, K. J., Choi, J., Lee, J., Bae, J. H., An, J. H., Kim, H. Y., Yoo, H. J., Seo, J. A., Kim, N. H., Choi, K. M., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0835-z · Cited by 26
Ferreira, J. P., Mehta, C. R., Sharma, A., Nissen, S. E., Rossignol, P., & Zannad, F. M. (2020) · BMC Medicine · doi:10.1186/s12916-020-01616-8 · Cited by 26
Zhang, X., Wang, M., Wang, X., Zhu, Z., Zhang, W., Zhou, Z., Tang, W., & Li, Q. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.12.007 · Cited by 26
Khera, R., Dhingra, L. S., Aminorroaya, A., Li, K., Zhou, J. J., Arshad, F., Blacketer, C., Bowring, M. G., Bu, F., Cook, M. B., et al. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000651 · Cited by 26
Roshanov, P. S., & Dennis, B. B. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.10.014 · Cited by 26
Clemens, K. K., Liu, K., Shariff, S. Z., Schernthaner, G., Tangri, N., & Garg, A. X. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12658 · Cited by 26
Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?
John, M., Unnikrishnan, A., Kalra, S., & Nair, T. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2016.02.017 · Cited by 26
DPP-4 Inhibitors and Heart Failure: Some Reassurance, Some Uncertainty
Filion, K. B., & Suissa, S. (2016) · Diabetes Care · doi:10.2337/dci15-0036 · Cited by 26
On behalf of the PROTECT Study Investigators, Tanaka, A., Murohara, T., Taguchi, I., Eguchi, K., Suzuki, M., Kitakaze, M., Sato, Y., Ishizu, T., Higashi, Y., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0449-7 · Cited by 26
Terauchi, Y., Yamada, Y., Ishida, H., Ohsugi, M., Kitaoka, M., Satoh, J., Yabe, D., Shihara, N., & Seino, Y. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12933 · Cited by 26
Fanaroff, A. C., Clare, R. M., Pieper, K. S., Mahaffey, K. W., Melloni, C., Green, J. B., Alexander, J. H., Jones, W. S., Harrison, R. W., Mehta, R. H., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037202 · Cited by 26
Self-citationSun, C., Sung, J., Wang, J., Li, C., Kuo, Y.-T., Lee, C.-C., Wu, J.-L., & Chang, Y. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223336 · Cited by 26
Metadata
- Authors
- Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., Lachin, J. M., McGuire, D. K., Pencina, M. J., Standl, E., Stein, P. P., Suryawanshi, S., Van de Werf, F., Peterson, E. D., & Holman, R. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Oxford (GB)
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Duke University (US)
- St. Michael's Hospital (CA)
- George Washington University (US)
- The University of Texas Southwestern Medical Center (US)
- Helmholtz Munich (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-16
- Volume
- 373
- Issue
- 3
- Pages
- 232-242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142830692
- Semantic Scholar
- 5f5aabad35a6c6137b19d8640d5d6cafc91815e5
- Cited by
- 2,577
- References
- 16
- Citations by year
- 2026: 68 · 2025: 121 · 2024: 120 · 2023: 139 · 2022: 170 · 2021: 210 · 2020: 289 · 2019: 267 · 2018: 343 · 2017: 343 · 2016: 378 · 2015: 120
- FWCI
- 341.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (acceptedVersion, cc-by-nc-nd)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- UNC Libraries
- Funders
- South Australian Health and Medical Research Institute
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- sitagliptin, type 2 diabetes, cardiovascular disease, DPP-4 inhibitors, major adverse cardiovascular events, heart failure hospitalization, acute pancreatitis, pancreatic cancer, HbA1c, glycemic control, non-inferiority
- MeSH terms
- Sitagliptin Phosphate, Administration, Oral, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Follow-Up Studies, Heart Diseases, Heart Failure, Glycated Hemoglobin, Hospitalization, Humans, Hypoglycemic Agents, Pyrazines, Triazoles, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
